BioPharma-Reporter.com |
Asthma: It's a mAb, mAb, mAb, mAb world says analyst
BioPharma-Reporter.com News that Sanofi and Regeneron's mAb alirocumab has lower cardiovascular risks than other cholesterol drugs may have grabbed recent headlines, but it is their asthma candidate, dupilumab , that has caught the eye of GlobalData analyst, Valentina … |
View full post on asthma – Google News